Olysio: further oral treatment option for chronic hepatitis C

The launch of Olysio (simeprevir) provides a further oral treatment for combination therapy in hepatitis C and can be used without concomitant interferon.

by
Olysio (simeprevir) is a new oral directly-acting antiviral for the treatment of hepatitis C
Olysio (simeprevir) is a new oral directly-acting antiviral for the treatment of hepatitis C

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package